Literature DB >> 11717409

IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients.

N Azimi1, M Nagai, S Jacobson, T A Waldmann.   

Abstract

IL-15 is a critical cytokine for the maintenance of memory-phenotype CD8 cells in mice. Here, we investigated the role of IL-15 in the neurological disease termed human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The high number of viral-specific CD8 cells in these patients is associated with inflammatory responses in the central nervous system. Because IL-15 is overexpressed in these patients, we asked whether IL-15 contributes to the persistence of human T cell lymphotropic virus I viral-specific CD8 cells. Using ex vivo cultures of HAM/TSP peripheral blood mononuclear cells, we demonstrated that in the majority of patients examined here blocking IL-15 action resulted in a decrease in the number of viral-specific CD8 cells. This decrease was caused by both inhibition of proliferation and induction of apoptosis in these cells. The data indicate that IL-15 plays a major role in the maintenance of viral-specific CD8 cells in HAM/TSP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717409      PMCID: PMC64721          DOI: 10.1073/pnas.251540598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Activated T lymphocytes in cerebrospinal fluid of patients with HTLV-I-associated myelopathy (HAM/TSP).

Authors:  S Ijichi; N Eiraku; M Osame; S Izumo; R Kubota; I Maruyama; M Matsumoto; T Niimura; S Sonoda
Journal:  J Neuroimmunol       Date:  1989-12       Impact factor: 3.478

2.  Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.

Authors:  W J Storkus; J Alexander; J A Payne; J R Dawson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

3.  Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.

Authors:  M Tsudo; F Kitamura; M Miyasaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

4.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I.

Authors:  S L Cross; M B Feinberg; J B Wolf; N J Holbrook; F Wong-Staal; W J Leonard
Journal:  Cell       Date:  1987-04-10       Impact factor: 41.582

7.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

8.  Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis.

Authors:  C E Parker; S Daenke; S Nightingale; C R Bangham
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

9.  Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Authors:  C L Tendler; S J Greenberg; W A Blattner; A Manns; E Murphy; T Fleisher; B Hanchard; O Morgan; J D Burton; D L Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

10.  HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease.

Authors:  S Jacobson; D E McFarlin; S Robinson; R Voskuhl; R Martin; A Brewah; A J Newell; S Koenig
Journal:  Ann Neurol       Date:  1992-11       Impact factor: 10.422

View more
  30 in total

1.  CD25+CD4+ T cells contribute to the control of memory CD8+ T cells.

Authors:  Masaaki Murakami; Akemi Sakamoto; Jeremy Bender; John Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

3.  Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

Authors:  Jonathan L Berkowitz; John E Janik; Donn M Stewart; Elaine S Jaffe; Maryalice Stetler-Stevenson; Joanna H Shih; Thomas A Fleisher; Maria Turner; Nicole E Urquhart; Gilian H Wharfe; William D Figg; Cody J Peer; Carolyn K Goldman; Thomas A Waldmann; John C Morris
Journal:  Clin Immunol       Date:  2014-09-28       Impact factor: 3.969

Review 4.  Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2007-01-11       Impact factor: 8.317

5.  Immunostimulation by induced expression of NKG2D and its MIC ligands in HTLV-1-associated neurologic disease.

Authors:  Nazli Azimi; Steven Jacobson; Yuetsu Tanaka; Lawrence Corey; Veronika Groh; Thomas Spies
Journal:  Immunogenetics       Date:  2006-03-28       Impact factor: 2.846

Review 6.  Functions of IL-15 in anti-viral immunity: multiplicity and variety.

Authors:  Katherine C Verbist; Kimberly D Klonowski
Journal:  Cytokine       Date:  2012-06-15       Impact factor: 3.861

Review 7.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Raya Massoud; Yoshimi Enose-Akahata; Yutaka Tagaya; Nazli Azimi; Asjad Basheer; Steven Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

9.  Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Authors:  Thomas A Waldmann; Kevin C Conlon; Donn M Stewart; TatYana A Worthy; John E Janik; Thomas A Fleisher; Paul S Albert; William D Figg; Shawn D Spencer; Mark Raffeld; Jean R Decker; Carolyn K Goldman; Bonita R Bryant; Michael N Petrus; Stephen P Creekmore; John C Morris
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

10.  Host's innate immune response to fungal and bacterial agents in vitro: up-regulation of interleukin-15 gene expression resulting in enhanced natural killer cell activity.

Authors:  Phay Tran; Rasheed Ahmad; Jingwu Xu; Ali Ahmad; José Menezes
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.